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Abstract 
Background: Propofol is a safe and widely used intravenous anesthetic agent, for which additional clinical uses 
including treatment of migraine, nausea, pain and anxiety have been proposed (Vasileiou et al. Eur J Pharmacol 
605:1–8, 2009). However, propofol suffers from several disadvantages as a therapeutic outside anesthesia including 
its limited aqueous solubility and negligible oral bioavailability. The purpose of the studies described here was to 
evaluate, in both animals and human volunteers, whether fospropofol (a water soluble phosphate ester prodrug of 
propofol) would provide higher propofol bioavailability through non-intravenous routes.
Methods: Fospropofol was administered via intravenous, oral and intraduodenal routes to rats. Pharmacokinetic and 
pharmacodynamic parameters were then evaluated. Based on the promising animal data we subsequently con-
ducted an oral and intraduodenal pharmacokinetic/pharmacodynamic study in human volunteers.
Results: In rats, bioavailability of propofol from fospropofol delivered orally was found to be appreciable, in the order 
of around 20–70%, depending on dose. Availability was especially marked following fospropofol administration via 
the intraduodenal route, where bioavailability approximated 100%. Fospropofol itself was not appreciably bioavailable 
when administered by any route except for intravenous. Pharmacologic effect following oral fospropofol was con-
firmed by observation of sedation and alleviation of thermal hyperalgesia in the rat chronic constrictive injury model 
of neuropathic pain. The human data also showed systemic availability of propofol from fospropofol administration 
via oral routes, a hereto novel finding. Assessment of sedation in human volunteers was correlated with pharmacoki-
netic measurements.
Conclusions: These data suggest potential utility of oral administration of fospropofol for various therapeutic indica-
tions previously considered for propofol.
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Background
Propofol (2, 6-diisopropylphenol) is an intravenous short-
acting anesthetic agent that has gained wide acceptance for 
inducing and maintaining anesthesia and for procedural 
sedation. Animal and clinical data suggest that propofol has 
a variety of non-hypnotic effects that may have therapeutic 
application at non-sedative doses [1, 2]. Propofol also has 
diverse pharmacology that might prove useful in several 
conditions, including prolongation of inhibitory postsynap-
tic currents mediated by GABA A receptors [3] as well as 
enhancing GABA release via presynaptic mechanisms [4].
Potential clinical utility for propofol has been reported 
in various conditions including anxiety [5, 6], migraine 
[7–10], analgesia [11, 12], emesis [13, 14] and pruritis 
[15–17], all at exposures below those causing sedation.
In spite of this potentially useful and unique pharma-
cology, the clinical use of propofol in other therapeutic 
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areas has been limited by its formulation as a short-act-
ing intravenous emulsion. Propofol’s insolubility in water 
requires its formulation in a lipid emulsion [18] using 
complicated manufacturing processes with ensuing lim-
ited storage time because of the risk of microbial con-
tamination [19]. Propofol is not orally bioavailable in 
animals or in humans [20, 21] possibly due to limited 
aqueous solubility, and first pass metabolism by the liver. 
It has been reported that intravenous administration of 
the lipid emulsion undergoes an extraction of 80% by the 
liver in animals [22–24] and in humans [25, 26].
Fospropofol (Lucedra™) is a water-soluble, phosphono-
O-methyl prodrug of propofol that was approved as an 
alternative to propofol for monitored anesthesia care 
during procedures in the United States [19, 27]. The 
aqueous solubility of fospropofol allows it to be formu-
lated for intravenous use without the oil in water emul-
sion formulation required for propofol. Fospropofol is 
rapidly metabolized by endothelial alkaline phosphatases 
to release propofol, phosphate and formaldehyde. For-
maldehyde is rapidly converted to formate and safely 
eliminated, similar to the other available phosphate 
methyl prodrugs such as fosphenytoin. Sedative effects 
appear to be due entirely to the propofol liberated from 
the prodrug. However, prodrug metabolism leads to dif-
ferences from propofol in its onset, peak effects and 
duration of action [19, 28, 29]. Fospropofol was generally 
well tolerated in clinical trials with only mild to moderate 
adverse events reports, mostly transient in nature [30]. 
Thus, as an intravenous sedative, fospropofol has sev-
eral advantages over propofol, including less pain at site 
of injection, less potential for hyperlipidemia with long-
term use and less chance of bacteremia in patients.
We hypothesized that the oral bioavailability of propo-
fol from fospropofol might differ from that of propofol 
due to its novel properties of water solubility and lack of 
emulsion formulation. In the animal and clinical stud-
ies reported here we demonstrate, for the first time, the 
successful delivery of propofol by administration of the 
prodrug fosprofol through the gastrointestinal tract, a 
property that may ultimately be exploited for clinical use.
Methods
Animal studies, drugs and formulations
Male Sprague–Dawley rats (Charles River, MD, USA) 
weighing 200–250  g were used, unless otherwise noted. 
Animals were housed in groups of three inch suspended 
polycarbonate cages (18 inch long, 9 inch wide and 9 inch 
high) under a 12 h light/dark cycle. Food (Harlan/Teklab) 
and water (filtered and delivered via an automatic water-
ing system) were provided ad libitum. All procedures 
were conducted in compliance with the laws, regulations 
and guidelines of the National Institutes of Health (NIH/
PHS) and with approval from the local Animal Care and 
Use committee.
For animal studies, fospropofol dosing solution was 
made by dissolving powder in water (for oral and intra-
duodenal administration) or saline (for intravenous 
administration) into an administration volume of 1 or 
2 mL/kg, as noted.
Pharmacokinetic studies in rats
Male Sprague–Dawley rats (225–250  g) underwent 
implantation with indwelling jugular vein catheters for 
plasma sampling. Animals receiving intravenous (IV) 
drug administration also underwent femoral vein cath-
eterization and, after full recovery were attached to an 
electronic infusion pump and administered vehicle or 
various concentrations of fospropofol in 1 mL total vol-
ume by gradual constant rate infusion over 10  min. 
Intraduodenal (ID) administration was via previously 
implanted catheters (HILLTOP Labs, PA) in a constant 
volume of 2  mL/kg body weight, by slow infusion. Oral 
administration (PO) was performed via a curved bulb-
tipped feeding gavage tube attached to a syringe inserted 
carefully through the oesophagus via the side of the 
mouth of manually restrained rats using an administra-
tion volume of 1  mL/kg. On the day of testing, control 
blood samples were taken from the jugular vein prior 
to dosing of test compounds in conscious rats. In these 
studies, intravenous doses were based on previously 
reported behavioral and pharmacokinetic studies with 
fospropofol. The PO and ID doses were established based 
on preliminary experiments with behavioral observa-
tion, using higher doses based on lower expected oral 
bioavailability.
After fospropofol administration, blood samples 
(0.5  mL) were taken at 5, 15, 30, 45, 60, 120, 240 and 
360 min post dose. An equivalent volume of blood taken 
from donor rats of the same strain was administered after 
each blood sample withdrawal, in an effort to maintain 
blood volume as previously described [31–33]. Approxi-
mately 0.05 mL of 200 mg/mL of sodium orthovanadate 
(SOV) solution was added to the heparinized blood col-
lection tubes prior to blood collection to prevent ex vivo 
conversion via alkaline phosphatases (ALP). The blood 
samples were mixed, cooled and subsequently centri-
fuged at 3,000 rpm and 4°C for 10 min within 30 min of 
collection. Plasma samples were stored at −20°C until 
analysis.
Sedative studies in rats
The relative potency of fospropofol given via different 
administration routes was investigated in rats, using 
sedation as an end point. Intravenous fospropofol doses 
of 5–40  mg/kg were chosen based on previous studies 
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[34]. Based on expected lower oral bioavailability, doses 
of 100–400 mg/kg were chosen for the PO and ID stud-
ies. Following administration of fospropofol, two experi-
mental observers blinded to the treatment, graded the 
behavior of the rats (n  =  2–3 per experimental group) 
every 5  min for a total of 120  min after administration. 
The scoring system was on a 0–4 scale where 0 =  alert 
and completely responsive, 1 = alert but less active and 
‘wobbly’, 2 = awake but drowsy with periods of in-activity 
or mild sedation, 3  =  inactive but readily arousable or 
moderately sedated, 4  =  unresponsive, unconscious or 
deeply sedated. Scores were averaged across treatment 
groups per time point.
Neuropathic pain studies in rats
This study was performed as previously described by our 
group [35]. In brief, male Sprague–Dawley rats (200–
250 g) were anesthetized with halothane. The common sci-
atic nerve on one hind limb was exposed by separating the 
biceps femoris from the gluteus superficialis. The nerve 
was subsequently isolated from the surrounding tissue and 
four ligatures (4.0 chromic gut) were tied loosely around 
it with about 1  mm spacing. On the other hind limb of 
the rat, the nerve was similarly isolated but no ligatures 
were placed, (sham surgery). Thermal pain sensitivity was 
evaluated using a plantar test apparatus according to pre-
vious methods [36]. In brief, this involved applying a con-
stant infrared stimulus  to the plantar surface of the hind 
paw using a Basile Plantar apparatus (Ugo Basile, Vaarese, 
Italy). Withdrawal latency was measured as the time taken 
for the rat to withdraw its paw from the heat source to 
the nearest 0.1 s. The “difference score” was calculated by 
subtracting the average latency of the non-ligated versus 
ligated side. Animals were habituated to the test chambers 
(clear plastic compartment maintained in a quiet room) 
for several hours over 3–4 days, prior to any measurement. 
Baseline hyperalgesia was recorded 10–12  days post-
surgery after the habituation. On test day, each animal 
received either fospropofol (50, 75 or 100 mg/kg) or vehi-
cle (distilled water) via oral gavage in a volume of 2 mL/kg 
in a randomized and blinded fashion. Withdrawal latency 
measurements were then recorded five times for both the 
operated and sham hind paws of each rat starting from 45 
to 60 min post dose. The final latency measurement repre-
sents a mean of the last four out of a total of five responses, 
each being taken at least 5 min apart on the same paw. The 
difference in response latency for each rat for each leg was 
calculated and used to determine the mean latency differ-
ence response time for each group.
Human studies, drugs and formulations
Human studies were approved by the institutional 
review boards at PRA Health Sciences in Groningen, 
Netherlands and were conducted in accordance with the 
ethical principles that have their origin in the Declaration 
of Helsinki and the International Conference on Harmo-
nization guideline E6: Good Clinical Practice. All partici-
pants provided written, informed consent before study 
entry and had the right to withdraw from the study at any 
time.
In human study 1, Fospropofol disodium was formu-
lated as a sterile aqueous solution at a concentration of 
20 mg/mL. Each vial provided contained 20 mL of solu-
tion, suitable for intravenous injection. Fospropofol was 
administered as a single dose of 400  mg orally, directly 
into the duodenum by gastroscopy or intravenously over 
10 min. In human study 2, fospropofol disodium in cap-
sules (200  mg) or matching placebo was administered 
orally.
Fospropofol studies in human volunteers
The first study was an absolute bioavailability study of 
fospropofol conducted at a single center (PRA Health 
Sciences) in Groningen, Netherlands, as a three-way 
crossover study. The study enrolled 7 healthy male vol-
unteers between 18 and 45  years of age inclusive, with 
a body mass index between 18 and 28  kg/m2. Subjects 
stayed in the clinical unit for three consecutive periods 
of 3  days each, with a 3-day washout, between periods. 
For six subjects, the order of the administration routes 
was as follows—period 1: PO, period 2: ID, and period 3: 
IV. For one subject the order of the administration routes 
was the following—period 1: ID, period 2: IV and period 
3: PO. In this study a single dose of 400 mg was admin-
istered by each route. Blinding and placebo control was 
impractical due to the requirement of unsedated endo-
scopic administration of fospropofol into the duodenum. 
Safety and overall pharmacodynamic effect was evaluated 
based on adverse events, vital signs, electrocardiogram 
(ECG), Modified Observer’s Assessment of Alertness/
Sedation (OAA/S) score, clinical laboratory tests, and 
physical examination.
A second single ascending dose study was subse-
quently performed to assess the safety, tolerability, and 
pharmacokinetics of oral administration of fospropo-
fol as a capsule. This was a double-blind, randomized, 
crossover, placebo-controlled, single ascending dose 
study. Ten healthy volunteers were enrolled, 6 males and 
4 females between 18 and 45 years of age inclusive with 
a body mass index between 18 and 28 kg/m2. Each sub-
ject received four ascending oral doses of fospropofol 
disodium (200, 600, 1,000 and 1,200 mg) and one of pla-
cebo. Placebo was administered randomly, in one of the 
five periods. Subjects stayed in the clinical research unit 
over 3 days per treatment for five consecutive treatments. 
Between treatments, there were wash-out periods of at 
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least 6 days, during which interim safety evaluations were 
made to assess the safety of the subsequent higher doses.
Fopropofol disodium in capsules (200  mg) or match-
ing placebo was administered orally. Pharmacokinetic 
parameters, safety and pharmacodynamic effect were 
assessed in a manner similar to that in Study 1 described 
above. In addition, the digit symbol substitution test 
(DSST) and BIS Index (a commercially available EEG 
derived measure of anesthesia and sedation, Coviden, 
Mansfield, MA, USA) were added as additional pharma-
codynamics measures.
In the first study, 6  mL blood samples were collected 
following the PO and ID fospropofol treatment periods 
at times of pre-dose, 5, 10, 20, 30, 45, 60, 90 min and 2, 
4, 6 and 9  h post-dose and in the IV fospropofol treat-
ment period at pre-dose and at 5, 10, 15, 20, 30, 45, 60 
and 120 min post-dose. In the second study a 6 mL blood 
sample was collected following each fospropofol PO dose 
(200, 600, 1,000 and 1,200 mg) at pre-dose, 5, 10, 20, 30, 
45, 60, 90 min and 2, 4, 6 and 9 h post-dose. The blood 
was collected in a sodium heparin vacutainer tube con-
taining 60 mg SOV, inverted approximately eight times to 
dissolve SOV and placed on dry ice until it was centri-
fuged at 3,000 rpm for 10 min at 4°C to harvest plasma. 
Plasma samples were then stored at −20°C until analysis.
Bioanalysis of propofol and fospropofol
Fospropofol and propofol in human and rat plasma were 
quantified using a validated high performance liquid 
chromatography (HPLC) with a tandem mass spectrom-
etry method (LC/MS/MS) and an HPLC fluorescence 
detection method respectively, as described below.
For fospropofol analysis, fospropofol-d6 (inter-
nal standard prepared in 1.0  M ammonium acetate 
buffer) was added to the plasma samples (rat or human: 
0.05 mL) and subsequently extracted using a solid phase 
extraction (SPE). The SPE cartridges were conditioned 
by gravity with methanol and 1.0  M ammonium ace-
tate solution in water. The plasma samples with inter-
nal standard were loaded on the cartridges, washed 
with water and 10% methanol/water and eluted with 
methanol. The tubes were then evaporated under nitro-
gen and the residues reconstituted with 50/50 metha-
nol/25  mM ammonium acetate in deionized water. The 
sample extract was then injected onto a reversed phase 
HPLC Zorbax Eclipse XDB-C18 column. The separated 
analytes were detected using tandem mass spectrom-
etry (MS/MS) detection. Fospropofol was quantitated 
by peak area ratio to its internal standard by mass spec-
trometry using a selective reaction monitoring mode 
(for fospropofol m/z  =  287.1  →  79.1, and for D6-fos-
propofol m/z  =  293.1  →  79.1). The assays were linear 
with correlation coefficient of (R2) >0.99 over the range 
of 10–2,000  ng/mL for rat plasma and 5–1,000  ng/mL 
for human plasma. Fospropofol was stable for 98  days 
at −20°C in rat plasma and 464 days at −20°C in human 
plasma.
The propofol plasma assay method was modified from 
an earlier published method by Plumb et al. [37]. In brief, 
4-[tert-octyl] phenol, (internal standard) was added to 
the plasma samples (0.05 mL for rat or 0.2 mL for human) 
and extracted using a 3M Empore C-18-SD 4  mm SPE 
cartridge (Millipore, Billerica, MA, USA). A mixture of 
plasma sample with drug and internal standard in ammo-
nium acetate buffer was passed through the SPE condi-
tioned with methanol and water. The SPE cartridge was 
further subjected to three wash steps; first with 1 mL of 
water, second with 1 mL of 10% methanol in water, and 
third with 20% acetonitrile in water. Finally the analytes 
were eluted using two times 0.15 mL of acetonitrile. The 
final eluants (~0.3 mL) were diluted with 0.3 mL of water, 
and injected onto an HPLC system equipped with a C-18 
analytical column (5 µm, 150 × 3.9 mm) and fluorescence 
detector set at excitation and emission wave lengths of 
275 and 310  nm, respectively. Propofol was quantitated 
by peak height ratio to internal standard. The assays were 
linear with correlation coefficient of (R2) >0.99 over the 
range of 5–2,000 ng/mL for both rat and human plasma. 
As reported by Shah et  al. [38], the precise measure-
ment of plasma propofol using this method may be com-
promised under conditions of severe hemolysis, as this 
causes insolubility of the added SOV during sample col-
lection which could result in incomplete ALP inhibition. 
Given this, hemolysis was avoided or minimized in both 
the preclinical and clinical studies by conducting sample 
processing in a cold environment. Propofol was found to 
be stable at −20°C for 65 days in rat plasma and 347 days 
in human plasma. All rat and human study samples in 
this study were analyzed without exceeding the stability 
sample integrity during validation of the methods.
Pharmacokinetic parameter calculations
Pharmacokinetic parameters were determined for fos-
propofol and propofol from plasma including area under 
the concentration–time curve from time of dosing to the 
last measured concentration (AUC(0-t)), peak concen-
tration (Cmax), time to reach maximum concentration 
(Tmax), terminal phase half-life (t1/2) and area under the 
concentration–time curve from time of dosing to infinity 
(AUC(0−∞)). Absolute bioavailability (F) was calculated as 
the ratio of AUC(0−∞) resulting from PO or ID adminis-
tration to AUC(0−∞) following IV administration, cor-
recting for the specific doses used. The parameters were 
summarized using descriptive statistics.
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Results
Bioavailability of fospropofol and propofol following IV, PO 
and ID dosing of fospropofol in rats
Following IV, PO and ID administrations the Cmax and AUC 
of fospropofol increased with dose (Table 1; Figure 1a–d). 
However, the increase in both parameters was less than 
dose proportional following IV administration and greater 
than dose proportional following both PO and ID admin-
istrations. The absolute bioavailability of fospropofol was 
low following both PO and ID administrations, ranging 
between 0.448 and 3.46% (PO 20 and 100 mg/kg) and 0.264 
and 1.03% (ID 30 and 100 mg/kg), respectively.
The Cmax and AUC of propofol increased with dose. 
The increase in Cmax and AUC was dose proportional 
for IV administration; in contrast, these parameters 
increased although not dose proportionally, following 
PO and ID administration (Table  2). The propofol bio-
availability following fospropofol administration via the 
Table 1 Mean (±SD) pharmacokinetic parameters of fospropofol following fospropofol administration in rats
nd not determined as only one rat showed terminal elimination.
a Ratio of mean of AUC(0−∞) to reference treatment of 5 mg/kg IV fospropofol.
b N = 1.
Route Dose (mg/kg) Cmax (µg/mL) AUC(0−t) (µg h/mL) AUC0−∞ (µg h/mL) T1/2 (h) Vd (L/kg) CLp (L/h/kg) F
a (%)
IV 5 16.3 (±1.80) 3.15 (±0.29) 3.15 (±0.28) 0.49 (±0.28) 1.02 (±0.66) 1.38 (±0.125) –
PO 20 0.23 (±0.07) 0.05 (±0.008) 0.06 (±0.007) 0.19 (±0.27) – – 0.448
PO 100 9.23 (±4.09) 2.16 (±0.99) 2.18 (±0.99) 0.49 (±0.24) – – 3.46
ID 30 0.17b 0.044 0.05 0.21nd – – 0.264
















































































































Figure 1 Plasma-concentration-time curves of fospropofol and propofol after intravenous, oral and intraduodenal administration of fospropo-
fol to rats. Intravenous administration of fospropofol (5 mg/kg) resulted in the expected immediate high concentrations of both fospropofol (a) 
and propofol (b). Oral administration of higher doses of fospropofol (20 or 100 mg/kg) resulted in lower peak fospropofol plasma exposure (c) but 
significant and prolonged propofol exposure (d). Intraduodenal administration of high doses (30 or 100 mg/kg) resulted in similar fospropofol levels 
in the plasma (e) but relatively higher peak propofol exposure (f). Data shown as mean ± SEM.
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PO and ID routes ranged between 22.7 and 70.5% (PO 20 
and 100  mg/kg fospropofol) and 47.3–141% (ID 30 and 
100 mg/kg fospropofol), respectively.
Sedative effects of PO and ID administration of fospropofol 
in rats
Intravenous administration of fospropofol rapidly induced 
a dose-related sedation at 10–40  mg/kg (Figure  2a). 
The sedative effects were evident within 1 min and abated 
within 30 min after infusion.
After PO administration, animals displayed a rapid 
(within 5–10  min of dosing) dose-dependent onset of 
sedated behavior, followed quickly by loss of conscious-
ness in the 300 and 400 mg/kg groups (Figure 2b), which 
lasted for up to approximately 1 h. Rats in the intermedi-
ate PO dose groups (100–200  mg/kg) displayed signs of 
mild to moderate sedation lasting about 1–2 h. In general, 
onset of sedation was slower and of longer duration after 
PO administration compared to the IV route (Figure 2a).
Similar to IV administration, ID fospropofol resulted 
in a similar rapid onset of sedation (within 5 min of its 
administration), followed by loss of consciousness in the 
higher dose groups. The onset of sedation was slightly 
faster than after PO administration and required lower 
doses (similar to those associated with the IV route) for 
the same maximal effect (Figure 2a, c). The duration of 
effect after ID administration was shorter than after PO 
administration at these lower doses, generally consistent 
with the time course predicted by pharmacokinetics.
Analgesic effects of PO fospropofol administration in rats
Fospropofol was active in alleviating thermal hyperalgesia 
in the rat chronic constrictive injury model of neuropathic 
pain at doses of 75 and 100 mg/kg PO, but not at 50 mg/
kg (Figure  3a). These effects were not due to general 
sedative effects as reflected by no change in latencies of 
response to stimuli on the sham (non-ligated side) in fos-
propofol treated rats vs vehicle (Figure 3b). In a separate 
study, rats (n = 10 per group) were dosed with fospropo-
fol PO at 75 mg/kg in a volume of 2 mL/kg. Withdrawal 
latency was then tested at different time points following 
dosing (1, 2 and 4 h). Fospropofol was effective only when 
tested at 1 h after administration and not after longer time 
periods (data not shown). Mean absolute latencies of ipsi-
lateral paw before and after fospropofol or vehicle treat-
ment are shown in Additional file 1: Figure S1.
Table 2 Mean (±SD) pharmacokinetic parameters of propofol following fospropofol administration in rats
a Ratio of mean of AUC(0−∞) to reference treatment of 5 mg/kg IV fospropofol.
Route Dose (mg/kg) Cmax (µg/mL) AUC(0−t) (µg h/mL) AUC0−∞(µg h/mL) T1/2 (h) F
a (%)
IV 5 0.29 (±0.04) 0.12 (±0.02) 0.14 (±0.03) ND ND
PO 20 0.04 (±0.001) 0.06 (±0.04) 0.13 (±0.12) 4.66 (±4.13) 22.7
PO 100 0.53 (±0.08) 1.21 (±0.2) 1.96 (±0.6) 4.13 (±1.12) 70.5
ID 30 1.27 (±0.87) 0.353 (±0.14) 0.398 (±0.14) 2.85 (±0.87) 47.3
















































































Figure 2 Sedation induced by fospropofol administered via a IV, 
b PO and c ID routes. The scoring system was on a 0–4 scale where 
0 = alert and completely responsive, 1 = alert but less active and 
‘wobbly’, 2 = awake but drowsy with periods of in-activity, 3 = gen-
erally sedated/inactive but readily arousable, 4 = unresponsive or 
unconscious. Sedative activity was assessed by blinded observers in 
2–3 rats per treatment group.
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Bioavailability of fospropofol and propofol in human 
volunteers following PO and ID fospropofol
Study 1 In this three way crossover study, absorption 
of fospropofol was rapid following PO and ID adminis-
trations, with Tmax of 0.08 and 0.17  h, respectively. The 
mean plasma concentrations of fospropofol declined rap-
idly after reaching Cmax (Figure  4a). Compared with IV 
fospropofol administration, the PO and ID fospropofol 
resulted in extremely low mean plasma concentrations 
of fospropofol. Compared with the Cmax of IV fospropo-
fol, the PO and ID Cmax values were approximately 88- 
and 534-fold lower, respectively (data not shown). The 
absolute bioavailability of fospropofol after PO and ID 
administration was very low (1% for PO and 0.1% for ID 
administration). The mean t1/2 of fospropofol was similar 
following all methods of delivery (0.32, 0.28, and 0.28 h 
for PO, ID and IV, respectively).
Compared with the Cmax of propofol after IV admin-
istration of fospropofol, the Cmax values after PO and 
ID administration were approximately five and three-
fold lower, respectively. The bioavailability (F), based 
on AUC(0−∞), of propofol was 30% for oral administra-
tion and 37% for ID administration. The liberation and 
appearance of propofol from fospropofol in systemic cir-
culation was rapid following ID and PO administrations 
with Tmax of 0.17 and 0.33  h, respectively. The t1/2 and 
Tmax for propofol tended to be longer after PO adminis-
tration than it was following ID and IV administrations 
(Figure 4b).
Study 2 In this oral dose escalation study, fospropo-
fol and propofol exposure showed dose related increase 
following PO doses of fospropofol in capsule form 
(Figure 5a–d).
Safety and tolerability of PO and ID fospropofol in human
Study 1 Seventy-three treatment emergent adverse 
events (TEAEs) were reported in 7 of 7 subjects (100%), 
(and are detailed in Additional file 2: Table S1). Seventy 

















































































Figure 3 Analgesic effect of orally administered fospropool in rat 
chronic constrictive injury model of neuropathic pain. Withdrawal 
latency measurements were taken starting 45–60 min post-dose. 
Fospropofol was effective in reducing hyperalgesia at doses of 75 
and 100 mg/kg (a). This effect was not due to a non-selective seda-
tive effect as latency on the non-ligated side did not change with 
fospropofol treatment (b). n = 10 rats per group. p < 0.05 vs vehicle 































   
   
   












































Figure 4 Pharmacokinetic profile of mean (±SEM) fospropofol 
and propofol concentrations in plasma following administration of 
fospropofol to human subjects by PO, IV and ID routes. A single dose 
of 400 mg was administered to seven volunteers in a sequential 
crossover design. Almost no plasma fospropofol was detected when 
administered by any non-intravenous route (a). In contrast, propofol 
bioavailability from fospropofol was substantial, ranging between 34 
and 48% respectively by AUC (b). Data shown as mean ± SEM.
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or probably related to study drug. The most frequently 
reported TEAEs were somnolence [11 events in 7/7 
subjects (100%)], paresthesia [10 events in 6/7 subjects 
(86%)], speech disorder [6 events in 6/7 subjects (86%)], 
and burning sensation [6 events in 3/7 subjects (43%)]. 
Two subjects (29%), one in the PO group and one in the 
IV group, reported one TEAE each of euphoria. Both 
events were mild, considered related to study medication 
and resolved after 17 and 34 min, respectively. No subject 
experienced a serious adverse event (SAE) and no subject 
discontinued from the study for any reason. These are 
detailed in Additional file 2: Table S1.
There was a marked difference in the number of treat-
ment-related TEAEs reported among the different routes 
of administration. When fospropofol was administered 
IV, 7 of 7 (100%) subjects reported 56 treatment-related 
TEAEs. When fospropofol was administered either PO 
or ID, 6 of 7 (86%) subjects in each group reported 8 and 
9 treatment-related TEAEs, respectively. No severe or 
serious TEAEs were reported during this study. There 
was no death or study discontinuation because of an AE. 
All but one TEAE (rash, which resolved without treat-
ment) resolved without sequelae within 1  h of dosing. 
The Investigator considered all TEAEs mild. No clini-
cally-relevant abnormalities were found with regard to 
clinical laboratory results, vital signs, ECG, or physical 
examination.
The Modified OAA/S scale was used to assess subjects’ 
level of sedation. The lowest observed Modified OAA/S 
score during this study was 4 (responded lethargically 
to name spoken in normal tone). Three of 7 (43%) and 4 
of 7 (57%) subjects in the ID and IV groups respectively, 
had a Modified OAA/S score of 4 at some time follow-
ing drug administration. All other subjects in those treat-
ment groups and all subjects in the oral treatment group 




















































































Dose Fospropfol Administered (mg)
Figure 5 Pharmacokinetic parameters of AUClast and Cmax for fospropofol (b and a) and propofol (d and c) following oral administration of placebo 
or fospropofol at 200, 400, 600, 1,000 and 1,200 mg in human subjects (n = 10). Each subject received each of the doses. In general, dose propor-
tional plasma concentrations of both fospropofol and propofol were observed. Data shown as mean ± SEM.
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(Modified OAA/S score of 5) at all times. All subjects 
had Modified OAA/S scores of 5 by 1.5 h postdose. This 
observation of similar sedation levels produced by IV and 
ID administration compared to PO administration are 
generally consistent with the pharmacokinetic measure-
ments that suggested somewhat higher duodenal than 
oral bioavailability.
Study 2 The patient incidence of TEAEs by treatment 
was: 40, 80, 90, 80, and 90% for placebo, 200, 600, 1,000, 
and 1,200 mg, respectively. (These are detailed in Addi-
tional file 2: Table S2). Somnolence was reported in 0, 40, 
50, 40, and 80% of subjects in the placebo, 200, 600, 1,000, 
and 1,200 mg groups, respectively. Following somnolence 
in rate of occurrence were paresthesia (60%), nausea 
(50%), and phlebitis superficial (50%). Most of the TEAEs 
were mild or moderate in severity and resolved without 
intervention. Two subjects (1 in the 1,000 mg treatment 
group and 1 in the 1,200  mg group) experienced som-
nolence that was considered severe by the Investigator. 
Only one TEAE (erythema in the placebo group, consid-
ered not related to study drug) required treatment and 
resolved before the end of the study. Euphoric mood was 
reported as a TEAE in three subjects during this study; 
one each in the placebo, 600, and 1,200 mg groups. There 
were no changes in laboratory values, vital signs, ECGs, 
or physical examinations that were considered clinically 
relevant by the Investigator during this study. No subject 
experienced a SAE and no subject discontinued from the 
study for any reason.
At most time points ≥80% of subjects in each of the 
treatment groups responded readily to their names spo-
ken in a normal tone (Modified OAA/S scores of 5). 
However, at the 1.5-h time point in the 1,200  mg treat-
ment group, 40% of subjects had a Modified OAA/S score 
of 4 (responded lethargically to their names spoken in a 
normal tone). The lowest Modified OAA/S scores (score 
of 3; responded only after name was called loudly and/or 
repeatedly) were recorded by the same subject (Subject 
003, following treatment with 1,000  mg), at 1 and 1½  h 
after treatment with fospropofol disodium.
DSST (digital symbol substitution test) performance 
decreased in a dose dependent manner. The maximal 
DSST changes from baseline for all fospropofol disodium 
treatment groups were recorded at the 1-h time point. 
At 1  h post-treatment, mean changes were 6, −5, −11, 
and −13 for the 200, 600, 1,000, and 1,200  mg groups, 
respectively. However BIS (bispectral index score) was 
not affected by fospropofol administration at any dose 
level where mean BIS scores were ≥90% at all the time 
points for all subjects following all treatments. Ranges 
were 67–98%, 80–98%, 71–98%, 70–98%, and 70–98% 
for the placebo, 200, 600, 1,000, and 1,200  mg groups, 
respectively.
Discussion
These results demonstrate for the first time that the water 
soluble prodrug fospropofol can be used to provide oral 
bioavailability of propofol in both rat and human. Previ-
ous reports concluded that propofol itself has little or no 
oral bioavailability, presumably due to first pass hepatic 
metabolism based upon liver extraction of 80% after 
intravenous administration of lipid emulsion in animals 
[22–24] and in human [25, 26]. In contrast, we observed 
that PO and ID fospropofol administration can achieve 
bioavailability of 30% or more. Interestingly, while propo-
fol availability derived from the prodrug is appreciable; 
the bioavailability of the prodrug itself is low, suggest-
ing that propofol is liberated from prodrug before enter-
ing the central compartment. This suggests that prodrug 
delivery allows propofol in the portal circulation to 
avoid first pass metabolism by the liver. GI administra-
tion resulted in a delayed, lower Cmax compared to intra-
venous propofol or fospropofol but was able to achieve 
plasma concentrations associated with sedation or anal-
gesia for an hour or more after a single administration. 
These results suggest for the first time that oral adminis-
tration of its prodrug may allow safe and practical admin-
istration of propofol at subhypnotic exposures for use in 
treatment of migraine, anxiety or other disease states.
We found that bioavailability and sedative effect varied 
by dose and location of administration in the GI tract of 
the rat. On a dose basis, fospropofol induced full sedation 
(an average score of 3.5 or higher, according to the 0–4 
rating scale described in “Methods”, for at least two con-
secutive recording times) when administered IV at a dose 
of 40  mg/kg. PO administration produced full sedation 
scores at 300–400 mg/kg, but only 50 mg/kg was required 
when administered ID. The time to reach effect and dura-
tion was similar through IV or ID routes, but slightly 
slower in onset and more prolonged following the larger 
doses required to reach sedation after oral administra-
tion, although comparable doses were not administered 
by both ID and PO routes. This suggests that, at least in 
rats, either the mechanism by which propofol liberated 
from fospropofol is dependent in part on the properties 
of the GI tract or that the conditions in the stomach may 
partially hydrolyze the prodrug to propofol in the lumen, 
rendering the propofol unavailable for absorption.
Measurement of plasma propofol in rats confirmed 
the greater bioavailability of ID compared to PO admin-
istration. Interestingly, bioavailability of fospropofol was 
consistently low when administered at either site in the 
GI tract, suggesting that the prodrug is hydrolyzed to 
release propofol prior to reaching the central compart-
ment. Relative propofol bioavailability rose with PO 
or ID doses, reaching 70% or more at the highest doses 
administered. The difference in dose required by the PO 
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route to achieve sedation appeared to be due largely to 
the lower Cmax even as propofol bioavailability increased 
on an AUC basis. The higher Cmax for the ID route corre-
sponded to a lower required dose for full sedation.
While food effect was not formally studied, it should 
be noted that all pharmacokinetic and sedative animal 
studies were conducted in the fasted state whereas the 
neuropathic pain studies were undertaken in rats with 
free access to food. It is likely that fospropofol would be 
deemed a class 1 drug under the Biopharmaceutics Clas-
sification System, due its high permeability and solubility, 
so that a food effect would not be expected. Future clini-
cal development of fospropofol through the oral route, 
however, would require a specific study of food effects.
The clinical observations described provide support-
ing evidence that fospropofol is bioavailable through the 
GI tract as well. Dose dependent sedative effects were 
observed in volunteers administered fospropofol orally 
by capsule in a dose response study.
The human pharmacokinetic data differed somewhat 
from rat, suggesting more equal bioavailability from PO 
and ID administration routes and less dose dependence 
of bioavailability. However there was lower bioavailability 
from capsules and significant variability in Cmax, suggest-
ing that a food effect may be likely and that a formulation 
providing predictable blood levels would be desirable, 
especially given the potentially narrow therapeutic win-
dow of propofol.
The bioavailability of fosproprofol through the GI 
tract is in marked contrast to the lack of bioavailability 
reported for propofol administered orally to rats and 
man in an oil/water emulsion formulation, rectally as an 
oil or in its pure form in soft gelatin capsules [22–24]. 
This has been explained in part by the high extraction of 
propofol by the liver in animals and man after intrave-
nous administration in an emulsion. Importantly, it has 
been shown that propofol can be absorbed buccally when 
administered in a semifluorinated alkane based formu-
lation [39] supporting the notion that liver metabolism 
likely limits oral bioavailability of propofol as oil in emul-
sion. Raoof et al. [23] studied the relative contribution of 
intestinal mucosa, liver and lung to in vivo disposition in 
the rat. In this study AUC’s of propofol were estimated 
and fractions of the administered dose escaping first pass 
metabolism by the gut wall (fa), liver (fh) and lung (fl) 
were calculated using propofol concentration following 
intra-arterial, intravenous, hepatic portal and oral routes 
of propofol administration. It was observed that the 
intestinal mucosa is the main site of first pass metabolism 
following oral administration of propofol in the rat. The 
liver and lung contribute much less compared to intes-
tinal mucosa. Intestinal metabolism could therefore also 
contribute to the systemic clearance of propofol. Due to 
first pass effect the observed bioavailability of propofol 
was low (10%).
The oral bioavailability of any drug may be limited by its 
aqueous solubility, low permeability, propensity to be an 
efflux substrate, and rapid and extensive hepatic metabo-
lism and biliary excretion. Raoof et al. [23] also reported 
that propofol is a highly permeable drug (evaluated using 
Caco-2 cell monolayers) and known to be a poorly solu-
ble drug. Therefore it can be classified as a biopharma-
ceutical class (BCS) class II drug. The oral bioavailability 
of this class of compounds is limited by solubility and not 
permeability. Our study data is consistent with fact that 
the propofol bioavailability is markedly higher following 
PO and ID administration of prodrug fospropofol due to 
its solubility. The absorbed fospropofol rapidly converts 
to propofol by alkaline phosphatase present in different 
organs including blood and liver. The low levels of fos-
propofol following PO administration further support 
this. Once propofol is in systemic circulation then its dis-
position is similar to that following IV administration.
Our data suggests that the prodrug is hydrolyzed at the 
gut wall or in the liver, liberating propofol into the cen-
tral compartment since the prodrug is not seen at appre-
ciable concentrations in the central compartment after 
oral administration. We assume that hydrolysis does not 
occur in the lumen of the gut, since that would result in 
very low bioavailability like that of propofol. We think 
it unlikely, based on the physiochemical properties of 
the phosphono-O-methyl prodrug, that fospropofol is 
absorbed across the gut wall to be hydrolyzed in the por-
tal vein or liver. Therefore it is most likely that hydroly-
sis takes place at the gut wall and propofol is delivered as 
free propofol into the portal vein.
This leaves the question of why propofol liberated from 
the prodrug at the gut wall is handled differently from 
propofol in emulsion. Propofol is known to be highly 
bound to serum proteins, particularly albumin [40]. It is 
therefore likely that propofol is cleaved at the gut wall 
and then rapidly diffuses to bind to plasma proteins. As a 
highly bound drug, extraction by the liver may be limited. 
The dose dependent increase in bioavailability is consist-
ent with observations that free propofol fraction is higher 
at low plasma propofol concentrations, thus enhancing 
clearance at low doses compared to higher doses where 
the free fraction is lower.
We hypothesize that the low bioavailability of propo-
fol administered orally or rectally as an emulsion or pure 
oil is due to propofol binding to plasma lipoproteins that 
facilitate its active uptake by the liver and subsequent 
metabolism. It has been shown that formulation has 
a significant effect on propofol distribution after intra-
venous administration with the emulsion formulation 
enhancing rapid brain effect and preventing pulmonary 
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distribution [39, 41, 42]. While propofol distribution and 
metabolism has been extensively studied in many spe-
cies and in clinical settings, major gaps remain in our 
understanding of its metabolism. For example, despite 
the high extraction ratio of propofol by the liver, during 
liver transplant only minor changes in propofol plasma 
concentration are observed, even as this major meta-
bolic site is removed during the anhepatic phase. Physi-
ological based modeling efforts have been attempted 
based on blood flow and tissue metabolism, but fail to 
predict clinical data and require adjustments to match 
clinical observations. It may be that intravenous infusion 
of propofol as emulsion is also influenced by factors such 
as lipoprotein vs albumin binding that constitute distinct 
and time varying pools of propofol that are not present 
when propofol is liberated from a water soluble prod-
rug. These considerations suggest that more detailed 
metabolic investigation comparing prodrug to emul-
sion might prove interesting, including measures of liver 
extraction of propofol from prodrug compared to emul-
sion when administered intravenously and through the 
gastrointestinal tract.
The oral bioavailability was sufficient to show anal-
gesic effects in a rodent neuropathic pain model. Non-
sedative doses of 75 or 100 mg/kg were effective after a 
single dose consistent with achieving plasma concentra-
tions greater than 200 ng/mL. Effects were of short dura-
tion, losing activity by 2 h after administration, consistent 
with the pharmacokinetic profile. These observations 
are consistent with previous reports of analgesic prop-
erties of intrathecal propofol in some acute pain models 
(e.g. phases 1 and 2 of formalin pain, hotplate and acetic 
acid writhing), but not in others (tail-flick test) [12, 43], 
and clinical observations of analgesic properties [11]. 
The demonstration of pharmacologic activity consistent 
with plasma concentrations confirms that propofol meas-
ured in the plasma is fully biologically active. It should 
be noted that recent publications have shown that envi-
ronmental enrichment can reduce pain perception in rats 
[44, 45]. The animals in this study, however, were not pro-
vided environmental enrichment. Future studies should 
monitor and compare the analgesic efficacy of propofol 
with and without enriching conditions.
The analgesic activity of propofol is consistent with 
its effects as a modulator of gamma-aminobutyric acid 
(GABA A) neurotransmission, in the spinal cord as well 
as the central nervous system [46]. Specifically, the effects 
of propofol on GABA A receptor mediated presynaptic 
inhibition at primary afferent terminals in the human spi-
nal cord [47] are thought to decrease spinal nociception 
[48]. The reported clinical effects of propofol on migraine 
and nausea may also be through GABAergic modulatory 
effects, although the definitive pathways have not been 
clearly described. Classical benzodiazepines that enhance 
GABA neurotransmission are not recommended as 
first line therapy for chronic pain because of CNS side 
effects and potential worsening of pain syndromes with 
prolonged use. It is possible however, that propofol’s 
analgesic effects may be mediated through additional 
mechanisms such as glutamatergic transmission, sodium 
channel blockade and NMDA/AMPA receptors [43, 49]. 
A recent publication [50] suggests that HCN (hyperpo-
larization activated, cyclic nucleotide regulated) chan-
nels may also mediate effects of propofol in neuropathic 
pain models. Regardless of precise mechanism, the clini-
cal utility of propofol oral administration as the prodrug 
would require longer clinical trials to ensure durable ben-
efit with good tolerability.
Our results suggest that the ability to deliver propofol 
through non-intravenous routes could enable therapeu-
tic utility of this broad pharmacology. Clinical experi-
ence and a number of trials provide substantial evidence 
of propofol’s clinical usefulness for treatment of epi-
lepsy, pain, nausea and migraine headache. These stud-
ies establish for the first time that, when administered as 
fospropofol, propofol is orally bioavailable in human vol-
unteers. Finally, in a well validated animal model of neu-
ropathic pain, analgesic effects can be demonstrated by 
oral administration.
Conclusions
Propofol is a widely used anesthetic/sedative agent whose 
diverse pharmacology has shown utility in several clini-
cal conditions including treatment of migraine, nausea, 
pain and anxiety. However its physical properties, includ-
ing limited solubility and negligible bioavailability via 
non-intravenous routes, have impeded its more wide-
spread use. Herein we show that oral administration of 
the fospropofol prodrug provides appreciable propofol 
bioavailability in both animal and in human volunteers. 
Furthermore we demonstrate pharmacological efficacy 
of oral fospropofol in animal models. These data sug-
gest utility of oral administration of fospropofol for vari-
ous therapeutic indications previously considered for 
propofol.
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